open access

Online first
Short communication
Published online: 2022-04-20
Get Citation

Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study

Dimitrios Patoulias1, Maria Toumpourleka2, Alexandra Katsimardou1, Ioanna Zografou1, Konstantinos Stavropoulos1, Konstantinos Imprialos1, Asterios Karagiannis1, Michael Doumas1, Christodoulos Papadopoulos2
DOI: 10.33963/KP.a2022.0104
·
Pubmed: 35445742
Affiliations
  1. 2nd Propaedeutic Department of Internal Medicine, General Hospital “Hippokration”, Aristotle University of Thessaloniki, Thessaloniki, Greece
  2. 3rd Department of Cardiology, General Hospital “Hippokration”, Aristotle University of Thessaloniki, Thessaloniki, Greece

open access

Online first
Short communication
Published online: 2022-04-20

Abstract

Not available

Abstract

Not available
Get Citation
Supp./Additional Files (1)
Supplementary material
Download
153KB
About this article
Title

Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Online first

Article type

Short communication

Published online

2022-04-20

Page views

18

Article views/downloads

19

DOI

10.33963/KP.a2022.0104

Pubmed

35445742

Authors

Dimitrios Patoulias
Maria Toumpourleka
Alexandra Katsimardou
Ioanna Zografou
Konstantinos Stavropoulos
Konstantinos Imprialos
Asterios Karagiannis
Michael Doumas
Christodoulos Papadopoulos

References (15)
  1. Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018; 17(1): 83.
  2. Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. Circ Res. 2019; 124(1): 121–141.
  3. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014; 57(4): 660–671.
  4. Tadic M, Cuspidi C, Vukomanovic V, et al. The influence of type 2 diabetes and arterial hypertension on right ventricular layer-specific mechanics. Acta Diabetol. 2016; 53(5): 791–797.
  5. Linssen PBC, Veugen MGJ, Henry RMA, et al. Associations of (pre)diabetes with right ventricular and atrial structure and function: the Maastricht Study. Cardiovasc Diabetol. 2020; 19(1): 88.
  6. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
  7. Nessler J, Siniarski A, Leszek P, et al. Reviewers. Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction. Kardiol Pol. 2021; 79(3): 363–370.
  8. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28(1): 1–39.e14.
  9. Sarak B, Verma S, David Mazer C, et al. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes. Cardiovasc Diabetol. 2021; 20(1): 200.
  10. Nassif ME, Qintar M, Windsor SL, et al. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial. Circulation. 2021; 143(17): 1673–1686.
  11. Chowdhury B, Luu AZ, Luu VZ, et al. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochem Biophys Res Commun. 2020; 524(1): 50–56.
  12. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018; 61(10): 2108–2117.
  13. Baartscheer A, Schumacher CA, Wüst RCI, et al. Empagliflozin decreases myocardial cytoplasmic Na through inhibition of the cardiac Na/H exchanger in rats and rabbits. Diabetologia. 2017; 60(3): 568–573.
  14. Quagliariello V, De Laurentiis M, Rea D, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021; 20(1): 150.
  15. Adingupu DD, Göpel SO, Grönros J, et al. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob mice. Cardiovasc Diabetol. 2019; 18(1): 16.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl